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Abstract
A sensitive method for immunocytochemical detection of estrogen receptors using flow cytometry is reported. Using this
method, estrogen receptors were detected in several osteoblastic cell lines with established expression of estrogen receptors,
and for the first time, estrogen receptors were also demonstrated in murine fibroblasts and in human primary marrow
stromal cells. The distribution of estrogen receptors within all cell lines was unimodal. The method enables for studies of
estrogen receptors in the cell types which express low to moderate levels of the receptors, for studies of heterogeneity of the
receptors’ expression and for simultaneous detection of several parameters on a single-cell level.
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1. Introduction
The role of estrogens in the maintenance of bone
mass in female subjects is well established. Until
recently, radioligand binding assay was the only reli-
able method for detection of ERs in osteoblast sys-
w x w xtems 1,2 . Ikegami et al. 3 were the first to report
successful detection of ERs in cultured bone cells
using immunocytochemical method. When applied to
flow cytometry, immunochemistry provides a suitable
tool for the quantitation of antigens on a single-cell
level and makes the parallel detection of several
markers convenient. Detection of ERs in female re-
Abbreviations: DMSO, dimethylsulfoxide; ER, estrogen re-
ceptor; FCS, fetal calf serum; FITC, fluorescein-isothiocyanate;
MeOH, methanol; NGS, normal goat serum; PBS, phosphate
buffered saline; PI, propidium iodide
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productive tissues using flow cytometry has been
w xused in experimental and clinical oncology 4,5 . In
this paper, we report for the first time a sensitive
modification of this method for it’s application in
bone biology.
2. Material and methods
2.1. Cell culture and isolation
MC3T3-E1 cells Riken Cell Bank, Koyadai,
.  .Japan , SaOS-2 cells ATCC, MD, USA , HOS TE-85
cells provided by Dr. T. Hall, Ciba-Geigy, Switzer-
. land and 3T3 cells provided by Dr. J. Jelınek,´
.Institute for Haematology, Czech Republic were
maintained in 25 cm2 culture flasks in humidified air
with 5% CO at 378C in Iscove’s modification of2
DMEM supplemented with 5% heat-inactivated FCS
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except for SaOS-2 cells, which were kept in 10%
.FCS , glutamate and antibiotics. The cells were sub-
cultured twice weekly with 0,25% trypsinr1 mM
EDTA at approx. 90% confluence. For the culture of
human marrow stromal fibroblasts, 20=106 of mar-
row cells a surplus from the marrow aspirate from a
.fertile female were seeded in the medium as above,
cultured at 328C and fed once weekly until confluent.
For flow cytometry experiments, the confluent cells
were detached by enzyme digestion. For histochem-
istry, the cells were grown on glass coverslips and
processed at desired time.
2.2. Fixation of the cells
For flow cytometry experiments, the cells were
fixed either with 90% methanol at y208C MeOH
.fixed or with 0.5% paraformaldehyder0.1% Triton
 . w xX-100 PFrTX fixed 6,7 . All manipulations were
at 48C unless otherwise specified. After enzymatic
digestion, 3=106 cells were washed once with PBS
and centrifuged. For MeOH fixation, the cells were
resuspended in 100 ml of PBS and overlaid with 900
ml of methanol at 708C both phases were mixed and
the cells were kept at y208C until used. Prior to
staining, the cells were centrifuged and washed once
with PBS. For PFrTX fixation, the cells were resus-
pended in 3 ml of 0.5% paraformaldehyde in PBS for
10 min. The cells were centrifuged, resuspended in 3
ml of 0.1% Triton X-100 and centrifuged. For im-
munohistochemical staining, the coverslips were
rinsed with PBS, fixed in 0.5% paraformal-
dehyderPBS for 10 min and treated with 0.1% Tri-
ton X-100 for 5 min. For the prolonged storage of the
cells, a method of freezing viable cells in DMSO was
adopted. The cells were stored in the freezing solu-
tion consisting of 10% DMSO, 40% FCS and 50%
PBS at y808C and kept until used. Standard samples
were prepared by pooling large number of the cells
and freezing aliquots of the cell suspension.
2.3. Staining of estrogen receptors
Two monoclonal antibodies directed against ER
were used: MA1-310 mouse IgG1, Affinity BioRe-
. agents, NJ, USA and ER1-D5 mouse IgG1, Im-
.munotech, France . Mouse IgG1 monoclonal anti-
 .body Sigma, cat. No. M-5284 was used as an
 X.isotype control. Biotinylated or FITC-labeled F ab 2
 .fragment of goat anti-mouse IgG Immunotech were
used as a secondary antibody. FITC-conjugated
 .streptavidin Immunotech was used as a third step in
the staining for flow cytometry and streptavidin-
peroxidaserDAB system StrAviGen kit, BioGenex
.Laboratories, CA, USA was used in immunohisto-
chemical staining. All manipulations were at 48C
unless otherwise specified; all solutions contained
0.05% Triton X-100. Washes were with 0.5 ml of
solution for 10 min, centrifugations were at 1800=g
for 4 min. For each sample examined, one test tube
was used with anti-ER antibody and one tube with
the same amount of isotype control. In the three-step
w xstaining protocol 8 , 1=106 of fixed cells were
incubated in 0.5 ml of 1:1 mixture of NGS and PBS
 .PBS-NGS for 30 min at 378C. The cells were then
resuspended in 100 ml of primary or control antibody
 .2.5 mgrml and incubated for 14–16 h in dark. The
cells were washed twice with PBS-NGS, incubated
with 50 ml of biotinylated secondary antibody 30
.mgrml for 2 h at room temperature and washed
once with PBS-NGS and once with PBS. Finally, the
cells were resuspended in 200 ml of streptavidin-FITC
 .in PBS 5 mgrml for 30 min and washed three
times with PBS. After the last centrifugation, the
cells were stained in 200 ml of PI in PBS 20
.mgrml for at least 30 min before flow cytometry.
Unless otherwise stated, PFrTX-fixed MC3T3-E1
cells and MA1-301 antibody were used in the experi-
ments. In the two-step technique, staining with pri-
mary and secondary antibodies were as described
above. However, FITC-conjugated instead of bio-
tinylated antibody was used in the second step. Fol-
lowing one wash in PBS-NGS and two washes in
PBS, the cells were stained with PI for 30 min before
analysis. Immunohistochemical staining for light mi-
croscopy was performed according to the protocol of
the three-step method. Staining and washing solutions
and incubation times were the same for the first two
steps, with 10 mgrml of primary antibody in the first
step. Streptavidin-peroxidaserDAB system was used
according to manufacturers recommendations.
2.4. Flow cytometry and data analysis
Measurements were performed on a FACScan in-
 .strument Becton-Dickinson . Fluorescence of FITC
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was collected through a 530r30 nm bandpass filter
set while PI fluorescence was collected through 585
nm filter; linear amplification was used for FITC and
logarithmic for PI signal. The instrument threshold
and photomultiplier settings were kept constant
throughout the study. For each sample 10 000 cells
were analysed. All data were analysed using Data-
 .MATE 3.0 software ACS, England . PI red fluores-
cence was used to gate the cells by DNA content to
eliminate the cell debris as well as the cell aggregates
from final analysis. A green fluorescence histogram
was used to display distribution of gated cells Fig.
.1 . To quantitate the number of ERs, specific fluores-
w xcence was calculated from the histogram 8 . For each
test, two samples were measured, one stained with
control antibody and the other one stained with anti-
ER antibody. Mean fluorescence was calculated for
both samples. Fluorescence of anti-ER-stained cells
represents the sum of the signal from both specific
and non-specific binding of antibodies and from other
 .sources autofluorescence, PI overlap ; it is referred
 .to as total fluorescence F . Fluorescence fromtot
control samples represents the sum of non-specific
signals only and is referred to as background fluores-
Fig. 1. Flow cytometry analysis of ER levels in MC3T3-E1 cells. Aliquots of fixed cells were stained with anti-ER or isotype control
monoclonal antibodies according to the three-step method to measure total and background fluorescence; PI fluorescence was used to gate
the cells by DNA content. to eliminate the cell debris from further analysis. On the forward versus 908 light scatter plot corresponding to
.  .the cell size and inner complexity, respectively of ungated population panel a , two overlapping subpopulations could be distinguished
 .marked R2 and R3 , corresponding to intact cells and subcellular particles, respectively. When only particles with complete DNA content
 .  .were included panel c, gate is marked R1 , they had predominantly the morphology of intact cells R2 panel b, region R2 . Subcellular
particles from region R3 had low PI fluorescence and were mostly excluded. A typical green fluorescence histogram of gated cells stained
 .  .with anti-E R antibody line or control antibody area is shown in panel d. Mean value was calculated for both histograms and2
 .  .  .background fluorescence F was subtracted from the total fluorescence F to obtain the value of specific fluorescence F , whichbgd tot sp
is the measure of specific binding of anti-ER antibody to ER.
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 .cence F . Specific fluorescence was calculatedbgd
 .F sF yF ; it is expressed as fluorescencesp tot bgd
units and is proportionate to an average estrogen
receptor number. To measure sensitivity of the
 .method, % Fsp was calculated % F sF rFsp sp tot
which is a ratio describing the ability of the method
to discriminate between specific and background sig-
nals. All results are presented in the text, table and
figures as the mean"SD.
3. Results
3.1. E˝aluation of fixation methods
MeOH and PFrTX fixation methods were com-
pared in terms of specific and background fluores-
cence. In six independent pairs of samples, a ratio
was calculated of values obtained with PFrTX and
MeOH methods for both F and F . The averagesp bgd
values were 1.85"1.24 for F and 0.79"0.13 forsp
F . Thus, F was 85% higher and F was 22%bgd sp bgd
lower in PFrTX fixed compared to MeOH fixed
cells. The average value of % F was 83.6% forsp
PFrTX method and 74.8% for MeOH. To test the
effect of freezing the cells in DMSO on the detection
of ERs, the ratio of F for fresh and frozen cells wassp
calculated for ten pairs of samples in four experi-
ments. The average value of the ratio was 1.24"0.17,
which was significantly different from 1.00 t-test,
.P-0.001 . Intraassay CVs for two identical sets of
 .five fresh vs. frozen cells 7.41% vs. 10.85% were
 .not significantly different t-test, P-0.05 .
3.2. Optimisation of staining protocol
Two monoclonal antibodies were compared for
 .their ability to detect ERs in human SaOS-2 and
 .murine MC3T3-E1 cells. Antibody MA1-310 con-
sistently provided better resolution compared to ER1-
D5. Average values of Fsp were 147"23 vs. 10"7
U for MC3T3-E1 cells and 82"18 vs. 5"3 U for
SaOS-2 cells. Effects of varying the concentration of
primary and secondary antibodies and streptavidin-
FITC on the F , F and % F are summarised insp bgd sp
Fig. 2 and in Table 1. The average ratio of F valuessp
for the three-step and two-step staining method was
 .Fig. 2. Titration of primary antibody upper panel and secondary
 .antibody lower panel . MC3T3-E1 cells were stained with vari-
ous concentrations of primary or secondary antibodies and F ,sp
F and % F values were calculated. Results are expressed asbgd sp
mean"SD, ns5. Secondary antibody concentration was 30
mgrml during primary antibody titration and primary antibody
concentration was 2.5 mgrml during secondary antibody titra-
tion. Streptavidin-FITC and PI concentrations were 5 mgrml and
20 mgrml, respectively.
 .2.38"1.06 ns5 . Average % F values weresp
81.4% and 59.8%, respectively.
3.3. Validation of the method
The intraassay variability of ER detection CV of
F values, seven consecutive measurements, fivesp
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Table 1
Effect of streptavidin-FITC concentration on F , F and % Fsp bgd sp
values
Concn.  .  .  .F U F U % F %sp bgd sp
 .mgrml
5 207"45 29"3 86.1"3.0
10 213"39 34"5 85.4"1.9
20 230"50 31"2 86.8"2.6
MC3T3-E1 cells were stained according to the three-step method;
various concentrations of streptavidin-FITC were used in the
third step. Concentrations of primary and secondary antibodies
and of PI were 2.5 mgrml, 30 mgrml and 20 mgrml, respec-
tively. Results are expressed as mean"SD of five experiments.
.replicates during each experiment , was 9.0%. The
interassay variability CV of the average F valuessp
obtained during five consecutive experiments, aver-
age values calculated from five replicates during each
.experiment , was 30.5%.
3.4. The expression of estrogen receptors in ˝arious
cell types
The values of F were 173"31 U for MC3T3-E1sp
cells, 116"22 U for SaOS-2 cells, 125"19 U for
HOS cells, 162"38 U for 3T3 cells and 151 U for
human marrow stromal cells. All cell types were
examined in 6–10 replicates in 2–5 independent
experiments with the exception of marrow stromal
cells, which were examined in duplicate in one exper-
iment. Unimodal distribution of fluorescence intensi-
ties were observed within each cell type, suggesting
that among the studied cells there were no distinct
subpopulations with respect to ER expression Fig. 1,
.panel d, Fig. 3 . This was also supported by the
results of immunohistochemical examination. Both
nuclei and cytoplasm showed staining for ERs in all
cell types. Slides stained with control antibodies
 .showed no detectable staining data not shown .
4. Discussion
The gain in resolution achieved by the three step
w xmethod 8 compared to the classical two step method
justifies the application of this method for the study
of bone cells. With MA1-310 antibody, higher total
fluorescence was obtained with PFrTX fixation com-
pared to MeOH method. In addition, this method is
w xknown to have lower background fluorescence 6 .
The amount of antibody used in a labelling reac-
tion needs to be selected with respect to the sensitiv-
ity required. A range of subsaturating concentrations
 .of primary antibody were tested Fig. 2, upper panel .
The values of % F did not change significantlysp
between 2.5 and 10 mgrml of antibody. Apparently,
relatively low increase in F was nearly offset by asp
w xcorresponding increase in F 8 . Therefore, 2.5bgd
mgrml seems to be satisfactory in terms of optimis-
ing % F .sp
Approximately 85–90% of antigen sites were la-
belled at 10 mgrml and 60% were labelled at 2.5
 .mgrml Fig. 2, upper panel . This fraction may be
expected to remain the same in cell lines with a
comparable antigen content if the differences in
antigen content were more than approximately five-
 .  .Fig. 3. Flow cytometry analysis of ER levels in SaOS-2 cells left panel and HOS TE-85 cells right panel . Staining and processing of
the cells was the same as described in Fig. 1.
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fold, the fraction of antigen labelled by the antibody
could change significantly and the comparison of
antigen content would not be quantitative. Similar
considerations hold for the titration of secondary
 .antibody Fig. 2, lower panel . Titration of strepta-
vidin-FITC did not show any significant change in
 .sensitivity or specific fluorescence Table 1 .
The intraassay variability of the method was within
the range expected for immunoassay. The interassay
variability of 30% reflects substantial complexity of
the whole procedure and would not necessarily ham-
per the results if suitable standard samples are used to
correct for the interassay variation of the method.
The present method appears a sensitive tool for the
relative quantitation of ERs in the cell types which
express low to moderate levels of ERs. To allow for
the direct quantitation of the number of ERs per cell,
specific the fluorescence detected by the present
method would have to be validated using a ligand
binding assay which provides absolute amounts of
hormone binding sites. As with the present results,
ERs were detected by the ligand binding in all of the
w xosteoblastic cell lines examined in this study 1,9–12
w xas well as in primary cultures of bone cells 2 .
However, a substantial variability among the results
was reported by different laboratories, reflecting
w xmethodological variations 13 . Moreover, conflicting
results were reported for identical cell lines examined
by independent groups, ranging from 0 to 2600 ERs
per cell for SaOS-2 cells and from 200 to 2200 ERs
w xper cell for HOS TE-85 cells 1,11,12 . Taking all
these literary results together, we assume that specific
fluorescence intensities reported in this paper for
different cell types correspond to the number of 500
to 2500 ERs per cell; however, comparing the present
results with those of ligand binding methods in any
particular laboratory would add little information of
biological significance to our observations.
For the first time we report the detection of ERs in
primary cultures of human marrow stromal cells and
in murine fibroblasts.
In addition to being an alternative method for
quantitation of ERs in bone cells, the use of flow
cytometry in this system provides a convenient ap-
proach to the studies of heterogeneity of ERs’ expres-
sion. Thus far, no distinct subpopulations of os-
teoblasts with respect to ER expression were detected
by a single-parameter data analysis. However, marked
heterogeneity in the expression of ERs in several
w xosteoblast like cell-lines was reported 3 , and cell-
cycle dependence of ER expression was reported for
MCF-7 breast cancer cells using synchronised cell
w xcultures 14 . It would also be of interest to study
simultaneously the changes in ERs and the markers
of osteoblast maturation, namely alkaline phosphatase
and osteocalcin, during the consecutive stages of
osteoblast maturation.
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